NCT06881784: An ongoing trial by Revolution Medicines, Inc.
This trial is ongoing. It must report results 2 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06881784 |
|---|---|
| Title | RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 6, 2025 |
| Completion date | Dec. 1, 2027 |
| Required reporting date | Nov. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |